The Cystic Fibrosis Foundation has awarded up to $5 million to Armata Pharmaceuticals to advance its potential…
Articles by Margarida Azevedo, MSc
AB569 is safe and effective at killing bacteria resistant to traditional antibiotics, in particular Pseudomonas aeruginosa (P. aeruginosa), an important disease-exacerbating…
A new non-invasive tool, called XV technology, allows professionals to visualize airflow in a living lungs and could help…
Vertex Pharmaceuticals recently gave an update on its Phase 3 development program, which consists of four studies, on the investigational compound VX-661…
ProMetic Life Sciences Inc. recently announced that Health Canada has approved the initiation of a clinical trial assessing the company’s anti-fibrotic lead…
Researchers at the Queen’s University Belfast developed a new compound that may change how lung ailments in cystic fibrosis (CF) are treated.
International Biophysics Corporation recently announced the publication of new data regarding the effectiveness of its AffloVest airway clearance technology…
People whose cystic fibrosis was detected through screening programs for newborns were found to have better growth throughout puberty and superior adult height, compared to…
Researchers at the University of Pittsburgh Center for Vaccine Research (CVR) have developed an engineered antimicrobial peptide effective against co-infection by bacterial…
The Cystic Fibrosis Foundation, a leading supporter of research funding for new cystic fibrosis (CF) treatments with the goal…